A practical maturity framework for teams comparing themselves to the validation lifecycle discipline used by stronger pharma, biotech, medical device, CDMO, lab, and GxP SaaS organizations.
Use this as a practical self-assessment. The goal is not more documentation. The goal is evidence that supports the risk, intended use, and release decision.
| Maturity | What It Looks Like | Business Impact |
|---|---|---|
| Reactive | System list is incomplete or owned by one person | Unknown GxP impact, stale ownership, audit scrambling |
| Managed | Systems have owners, intended use, and GxP impact classification | Good baseline, but periodic review may still be manual |
| Leading | Inventory drives validation scope, review cadence, change impact, and risk dashboards | Portfolio-level validation control |
Use this as a practical self-assessment. The goal is not more documentation. The goal is evidence that supports the risk, intended use, and release decision.
| Maturity | What It Looks Like | Business Impact |
|---|---|---|
| Reactive | Traceability matrix is created at the end or missing links | Weak release rationale and slow audit response |
| Managed | URS, risk, tests, deviations, and approvals are connected | Defensible validation package |
| Leading | Traceability updates continuously as systems change | Inspection-ready evidence without document archaeology |
Use this as a practical self-assessment. The goal is not more documentation. The goal is evidence that supports the risk, intended use, and release decision.
| Maturity | What It Looks Like | Business Impact |
|---|---|---|
| Reactive | Part 11 is handled as a checklist after implementation | Unsupported assumptions around audit trails, signatures, and access |
| Managed | Controls are assessed against intended use and procedures | Clear electronic record and signature rationale |
| Leading | Part 11 impact is embedded in vendor qualification, change control, and periodic review | Sustainable compliance posture |
Use this as a practical self-assessment. The goal is not more documentation. The goal is evidence that supports the risk, intended use, and release decision.
| Maturity | What It Looks Like | Business Impact |
|---|---|---|
| Reactive | Every function is tested with the same weight | Slow validation, low-value evidence, change fatigue |
| Managed | Testing depth follows patient safety, product quality, and data integrity risk | Focused assurance and better review quality |
| Leading | Critical thinking is documented, reusable, and accepted by QA | Faster releases with stronger rationale |
Use this as a practical self-assessment. The goal is not more documentation. The goal is evidence that supports the risk, intended use, and release decision.
| Maturity | What It Looks Like | Business Impact |
|---|---|---|
| Reactive | Evidence is spread across folders, emails, screenshots, and vendor PDFs | High stress and inconsistent answers |
| Managed | Packages include scope, plan, requirements, risk, tests, deviations, approvals, and summary | Prepared response to common audit questions |
| Leading | Audit package is generated from the lifecycle record | Fast, consistent, role-based inspection support |
VLMS can run a validation readiness review across systems, evidence, SOPs, Part 11 posture, CSA maturity, and audit retrieval risk.